ATRC News and Press, AtriCure Inc. From 11/12/19

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual Healthcare Conference in New York City. Atr...

AtriCure Inc (NASDAQ:ATRC) Q3 2019 Earnings Conference Call Oct 30, 2019, 4:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and Chief Executive Officer Andrew Wade - Senior Vice President and Chief Financial Officer Conference Call Participan...

Image source: The Motley Fool. AtriCure Inc   (NASDAQ: ATRC) Q3 2019 Earnings Call Oct 30, 2019 , 4:30 p.m. ET Operator Continue reading

AtriCure (NASDAQ: ATRC ): Q3 GAAP EPS of -$0.25 beats by $0.06 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. ( Nasdaq: ATRC ), a l...

AAPL , ACA , ACAD , ADTN , AGI , AGNC , AKS , ALEX , ALSN , APA , ARES , ATRC , AWK , AXTI , AZPN , BFAM , BLDP , BOOT , CACI , CATM , CERS , CF , CHDN , CHEF , CLI , CLR , CMPR , CNMD , CNXN , COLM , CONE , CREE , CRUS , CRY , CSGS , CTSH , CW , DDD , ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019. AtriCure will host a conference cal...

Thinly traded AtriCure ( ATRC +6.8% ) is up on average volume, a modest 200K shares, as JPMorgan steps in to defend the stock after yesterday's  10%  selloff in apparent reaction to a bearish report from Culper Research . More news on: AtriCure, Inc., Healthcare stocks news, S...

Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced ...